Deepak Nath

Deepak Nath serves as CEO of Smith & Nephew, a British medical devices company specializing in three main areas: Orthopaedics (hip and knee replacement implants, trauma fixation devices — used in joint replacement surgeries that restore mobility), Sports Medicine & ENT (arthroscopic cameras, shavers, and repair devices for minimally invasive surgery on knees, shoulders, and other joints), and Advanced Wound Management (negative pressure wound therapy, advanced wound dressings, and skin substitutes for chronic and acute wounds). Smith & Nephew has historically underperformed its orthopedic peers (Stryker, Zimmer Biomet, DePuy/J&J) in growth and execution, leading to periods of activist investor pressure and CEO changes. The new leadership is focused on a 12-point operational improvement plan targeting commercial execution, innovation acceleration, and margin expansion. The orthopedic market benefits from powerful demographic tailwinds: aging populations globally drive increasing demand for hip and knee replacements, sports medicine procedures grow as active lifestyles extend into older age groups, and wound care demand rises with diabetes prevalence (diabetic wounds are a major market). Key stock drivers include orthopedic procedure volumes, market share trends versus Stryker and Zimmer, sports medicine innovation, wound care growth, operating margin improvement, China volume-based procurement impact, and the execution of the turnaround plan.